Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Periprocedural myocardial necrosis after elective percutaneous coronary intervention (PCI) is a concern.
• The comparative efficacy of ticagrelor versus clopidogrel in patients with or without prior clopidogrel therapy remains unclear.

Purpose of the Study:

• To compare ticagrelor and clopidogrel in patients undergoing elective PCI.
• To assess the impact of prior clopidogrel therapy on outcomes.

Main Methods:

• A prespecified analysis of the ALPHEUS trial.
• Patients were categorized as clopidogrel-naive or clopidogrel-treated (≥7 days prior).
• Primary endpoint: composite of PCI-related myocardial infarction and major injury within 48 hours.

Main Results:

• 1,882 patients were analyzed; 42.7% were clopidogrel-treated.
• Clopidogrel-naive patients had lower rates of the primary endpoint (32.8% vs. 40.0%).
• Ticagrelor did not reduce periprocedural myocardial necrosis or adverse outcomes compared to clopidogrel, irrespective of prior treatment.

Conclusions:

• Clopidogrel-naive patients experienced fewer periprocedural complications due to lower risk profiles and less complex PCI.
• Baseline clopidogrel status did not alter the similar efficacy of ticagrelor and clopidogrel regarding PCI-related complications.
• Clopidogrel remains a standard of care for elective PCI in patients with or without chronic clopidogrel treatment.